Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Ph+ CML or Ph+ ALL who are primarily refractory to full-dose imatinib (600 mg), have disease progression/relapse while on full-dose imatinib, or are intolerant of any dose of imatinib.~* At least 3 months post stem cell transplantation~* Able to take daily oral capsules/tablets reliably~Exclusion Criteria:~* Subjects with Philadelphia chromosome, and bcr-abl negative CML~* Overt leptomeningeal leukemia~* Subjects without evidence of leukemia in bone marrow (extramedullary disease only)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SKI-606 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).